Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy
In this study, TROP2 expression by IHC was observed in all HR+/HER2- BC cases, and was not significantly correlated with pCR to NAC. In contrast, TACSTD2 expression, which was significantly positively correlated with survival in the same population, suggests a favorable prognostic value at the transcript level. This finding warrants further investigation in future studies, particularly focusing on TACSTD2 expression at the mRNA rather than the protein level.
Authors
- Olivier Cexus (ORCID: https://orcid.org/0000-0003-3773-3323)
- Laila M. Farid (ORCID: https://orcid.org/0000-0003-1992-5006)
- Mariam B. Abouelkhair
- Mahmoud Elghazawy (ORCID: https://orcid.org/0000-0002-3100-7606)
- Paul A. Townsend (ORCID: https://orcid.org/0000-0001-8956-9508)
- Shazneil Briones
- Hamdy A. Azim
- Hagar Elghazawy
- Sara Hossam
Institutions
- Ain Shams University (EG)
- University of Stirling (GB)
- Cairo University (EG)
- University of Surrey (GB)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1093/oncolo/oyaf184
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52